transparent gif


Ej inloggad.

Göteborgs universitets publikationer

Sequential Radioimmunotherapy with (177)Lu- and (211)At-Labeled Monoclonal Antibody BR96 in a Syngeneic Rat Colon Carcinoma Model.

Författare och institution:
Sophie E Eriksson (-); Erika Elgström (-); Tom Bäck (Institutionen för kliniska vetenskaper, sektionen för onkologi, radiofysik, radiologi och urologi, Avdelningen för radiofysik); Tomas Ohlsson (-); Holger Jensen (-); Rune Nilsson (-); Sture Lindegren (Institutionen för kliniska vetenskaper, sektionen för onkologi, radiofysik, radiologi och urologi, Avdelningen för radiofysik); Jan Tennvall (-)
Publicerad i:
Cancer biotherapy & radiopharmaceuticals, 29 ( 6 ) s. 238-246
Artikel, refereegranskad vetenskaplig
Sammanfattning (abstract):
Abstract Alpha-particle emitters, such as astatine-211 ((211)At), are generally considered suitable for the treatment of small cell clusters due to their short path length, while beta-particle emitters, for example, Lutetium-177 ((177)Lu), have a longer path length and are considered better for small, established tumors. A combination of such radionuclides may be successful in regimens of radioimmunotherapy. In this study, rats were treated by sequential administration of first a (177)Lu-labeled antibody, followed by a (211)At-labeled antibody 25 days later. Methods: Rats bearing solid colon carcinoma tumors were treated with 400 MBq/kg body weight (177)Lu-BR96. After 25 days, three groups of animals were given either 5 or 10 MBq/kg body weight of (211)At-BR96 simultaneously with or without a blocking agent reducing halogen uptake in normal tissues. Control animals were not given any (211)At-BR96. Myelotoxicity, body weight, tumor size, and development of metastases were monitored for 120 days. Results: Tumors were undetectable in 90% of the animals on day 25, independent of treatment. Additional treatment with (211)At-labeled antibodies did not reduce the proportion of animals developing metastases. The rats suffered from reversible myelotoxicity after treatment. Conclusions: Sequential administration of (177)Lu-BR96 and (211)At-BR96 resulted in tolerable toxicity providing halogen blocking but did not enhance the therapeutic effect.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
Klinisk medicin ->
Radiologi och bildbehandling ->
Postens nummer:
Posten skapad:
2014-07-10 11:39
Posten ändrad:
2014-07-30 13:28

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007